(S)-Ro 32-0432 (10-50 mg/kg; oral administration; once; female AHH/R rats) treatment inhibits subsequent phorbol ester-induced edema in rats demonstrating the systemic efficacy of the compound to inhibit PKC-driven responses. Induction of more physiologically T-cell driven responses such as host vs. graft responses and the secondary paw swelling in adjuvant-induced arthritis are also inhibited by Ro 32-0432[1].
According to the laws, regulations and policies related to "patent products", the sale of this product is prohibited!
ChemicalBook prompt
The patent owner or licensee of the product has not released any relevant information for the time being.
Product Name*
CAS.No
Inquiry Amount*
Port*
Inquiry Description*
+Add Attachment (File Format: Jpg, Gif, Png, PDF,Zip,Txt,doc or xls Max Size: 3MB)
Remove